Guggenheim analyst Yatin Suneja downgraded Biogen to Neutral after taking over coverage of the name, citing his belief that growth in its flagship Eylea product is abating and the launch of competitive products and biosimilars could lead to pricing pressure. The analyst lowered his price target for the shares to $325 from the firm’s prior $410 target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.